This most recent twist within the Lykos Therapeutics saga threatens a major overhaul of the organization’s method and route, with Musk ally and billionaire investor Antonio Gracias showing up to desire to just take the company back again towards its nonprofit drug development roots and a more Doblinite philosophy.Patent applications are secret fo